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Background: The aim of this report is to address treatment outcomes of patients with early-stage seminoma in a
single institution with special reference to patients with history of surgical violation of the scrotum.
Methods: Seventy four patients with pure seminoma were treated at King Hussein Cancer Center (Amman, Jordan)
between 2003 and 2010. All patients underwent orchiectomy. All but 3 patients received adjuvant radiotherapy.
Patients who underwent surgical violation of the scrotum prior to referral were managed by further excision or
irradiation of the scrotal scar. The follow-up ranged from 1 to 200 months (mean, 33 months).
Results: At the time of follow-up; all but one patient remain alive. The 3-year relapse-free survival for the entire
cohort was 95.9%. Three patients developed relapse, all of whom received adjuvant irradiation following inguinal
orchiectomy and initially harbored tumors larger than 4 cm upon pathological examination. Median time to relapse
was 14 months (range, 8–25 months). None were associated with elevated tumor markers prior to detection of
relapse. All but one patient were successfully salvaged by chemotherapy.
Conclusions: Our results confirm the excellent prognosis of patients with early-stage seminoma treated by
orchiectomy and adjuvant radiotherapy in a developing country. Although all patients who developed relapse
demonstrated adverse pathological findings upon initial assessment, no consistent predictor of relapse was found.
Scrotal scar re-excision or irradiation in patients with prior history of surgical violation of the scrotum are effective
measures in preventing local failure.Background
Testicular cancer is the most common malignancy in
men 20 to 40 years of age [1]. More than half of patients
with testicular cancer are found to harbor a seminoma
[2]. Over the past years, there has been a continuously
increasing incidence of testicular seminoma in the Western
world and Japan [3,4]. In the United States, 8480 new cases
and 350 deaths were expected in 2010 [5]. Seventy to eighty
percent of seminoma patients present with stage I disease
[2]. High inguinal orchiectomy is the standard initial treat-
ment [1]. Due to the lack of comparative randomized trials,
the choice of the most appropriate adjuvant management
approach remains controversial [2]. Adjuvant radiotherapy
is associated with a low rate of relapse set at 3-4% and
remains the standard treatment in the United States and
the most frequently used adjuvant modality in Europe [2].* Correspondence: jkhader@khcc.jo
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reproduction in any medium, provided the orRegardless of management strategy, virtually all patients
are cured [5].
Disappointingly, there is paucity of data assessing achiev-
able outcomes of seminoma patients outside developed
countries. The aim of this report is to address treatment
outcomes in patients with early-stage seminoma in a
developing country with special reference to patients who
underwent surgical violation of the scrotum.Methods
Between January 2003 and December 2010; seventy four
patients with histologically-confirmed pure seminoma
(classical and anaplastic subtypes) were treated at King
Hussein Cancer Center (KHCC) (Amman, Jordan).
Records were electronically retrieved and retrospectively
reviewed following acquisition of KHCC Institutional Re-
view Board approval (approval number; 10 KHCC 55).
Research conducted in this study was in compliance with
the Helsinki Declaration. Exhaustive chart analysis was
performed in an attempt to extract data pertaining toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient characteristics of the entire cohort
Patient characteristic Number (%)
Type of orchiectomy
- Inguinal approach 67 (90.5%)
- Scrotal approach 7 (9.5%)
Re-excision of scrotal scar 3
Local radiation to scrotal scar 4
Laterality
- Right 43 (58.1%)
- Left 29 (39.2%)
- Bilateral 1 (1.35%)
- Unknown 1 (1.35%)
Histology
- Classical seminoma 68 (91.9%)
- Anaplastic seminoma 6 (8.1%)
Tumor stage (assessable in all patients)
- T1 59 (79.7%)
Khader et al. BMC Urology 2012, 12:10 Page 2 of 7
http://www.biomedcentral.com/1471-2490/12/10pathological characters, clinical stage, treatment, disease
outcome and survival. Written informed consent was
obtained from all patients. Patients were evaluated with
thorough history, complete physical examination and
computed tomography (CT) of the chest, abdomen and
pelvis. Pathological diagnosis was confirmed by examining/
re-examining surgical specimens obtained via ochiectomy
by a staff pathologist at KHCC. Patients were classified
according to the 2002 American Joint Committee on
Cancer-International Union Against Cancer classification
[6] and were included for analysis if they exhibited stage I
disease with no clinical and/or radiological evidence of
distant metastases at the time of diagnosis. Cases were dis-
cussed at a joint care conference prior to therapeutic deci-
sions and delivery of care. Initial therapy consisted of
inguinal orchiectomy followed by adjuvant radiotherapy in
most patients. Complete blood counts and appropriate
serum markers (β-human chorionic gonadotropin (β-
HCG), lactate dehydrogenase (LDH), and α-feto protein
(AFP)) were obtained in a proportion of patients prior and
subsequent to surgery and at the time of follow-up.
Long-term fertility data were not available for this re-
port; however, all patients were offered sperm banking
prior to initiation of radiotherapy.
Radiation therapy was delivered via an appropriate en-
ergy Elekta linear accelerator (Elekta Oncology Systems,
Crawley, UK). Conventional or CT simulation was per-
formed in all patients. The para-aortic and dog-leg fields
were treated via a two-field parallel-opposed technique to a
total dose ranging from 2000 to 2500 cGy given over a
period of 2 to 3 weeks (daily fractions in 5 consecutive days
of the week). Standard, previously published, field designs
were utilized [7]. Figure 1 shows a typical para-aortic field.
Follow-up visits were conducted every 3 months for
the first 2 years after radiotherapy and every 6 months
thereafter. Clinical examination and analysis of AFP,
LDH and β-HCG levels were recorded if available. CT
scans of chest, abdomen and pelvis were performed twice
a year for the first 2 years and annually thereafter for aFigure 1 Isodose distributions and antro-posterior digitally
reconstructed radiograph of a typical PA field.total of 10 years. Acute and late radiotherapy-related side
effects were recorded during radiotherapy and at each
follow-up visit, respectively. Follow-up was in the form
of a patient visit to a staff clinician at KHCC or retrieval
of institutional-tumor registry and national data archives.
Results
The median age of our study population was 34 years
(range, 17–51 years). All patients underwent orchiectomy;
67 (90.5%) of which were performed via the inguinal ap-
proach. Seven patients were referred to our center following
scrotal-approach orchiectomy. These patients were treated
by further excision of the surgical scar (3 patients) or local-
field irradiation of the scrotal scar delivered via an add-
itional electron beam (4 patients). Fifty nine (79.7%)
patients harbored T1 while 15 (20.3%) harbored T2 disease.
None of the included patients had documented previous
history of ipsilateral pelvic surgery. All but 3 patients- T2 15 (20.3%)
Adjuvant radiotherapy 1 71 (95.9%)
- Para-aortic field 63 (88.7%)
20 Gy/10Fx 48
25 Gy/15Fx 15




- Local 0 (0%)
- Regional 1 (1.3%)
- Distant 2 (2.7%)
1: One patient received radiation at outside facility, no further details were
available for this patient.
Figure 2 Progression free survival of the entire cohort.
Figure 3 Co-registration of CT scan demonstrating recurrence
with the panning CT scan; recurrence is in-field.
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(88.7%) patients or dog-leg fields in 7 patients (9.9%)
(Table 1). The mean time form orchiectomy to initiation of
radiotherapy was 57.9 days. Acute radiotherapy-related side
effects were mild in all patients, while none demonstrated
late toxicity at the time of follow-up. The length of follow-
up -for the whole cohort- ranged from 1 to 200 months,
with a mean follow-up period of 33 months. The median
time of follow-up for the 3 patients who were kept on active
surveillance was 37 months (range, 12–77 months). None
of whom had developed disease relapse.
At the time of follow-up; all but one patient were alive.
The 3-year relapse-free survival for the entire cohort was
95.9% (Figure 2). Three patients developed relapse, all of
whom received adjuvant irradiation following inguinal
orchiectomy and initially harbored tumors larger than
4 cm upon pathological examination. Median time to re-
lapse was 14 months (range, 8–25 months). The site of
failure was regional in 1 patient and distant in 2 patients.
CT scan of the abdomen in the patient harboring re-
gional recurrence was compared with simulation CT
demonstrating that this recurrence was actually in-field
(Figure 3). Relapse was initially detected via clinical
examination in 1 and computed tomography in 2
patients. None were associated with elevated tumor
markers prior to detection of relapse (Table 2). Preopera-
tively, eleven patients (13.1%) demonstrated abnormal β-
HCG while 2 patients (2.4%) had abnormal LDH.
However, none of the patients with previous history of
abnormal tumor markers developed relapse. All but one
patient were successfully salvaged by chemotherapy
(details of the administered chemotherapy protocols arementioned in Table 2). After a median follow-up of
28 months (range, 7–74 months), and subsequent to re-
excision or local irradiation of the scrotal scar, none of
the 7 patients with prior history of surgical violation of
the scrotum developed relapse (Table 3).Discussion
Forty four testicular tumor cases were reported in the
Jordanian national cancer registry in 2008. Although
these neoplasms came short from ranking among the 10
leading cancer subtypes amongst males overall, testicular
tumors ranked 7th and 5th amongst males aged 0–19
and 20–49 years, respectively [8]. Since there are no
detailed epidemiological studies addressing seminoma in
Jordan, we have compiled a chart depicting the temporal
distribution of stage I seminoma cases treated at our
center over the years of this study (Figure 4).




































1 40 T1 Inguinal Para-aortic
(20 Gy/10Fx)
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(20/10Fx)
6 cm tumor Not
available
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BEP: Bleomycin, Etoposide, Cisplatin, TIP: Paclitaxel, Ifosfamide, Cisplatin, VIP: Etoposide, Ifosfamide, Cisplatin, GOP: Gemcitabine, Oxaliplatin, Paclitaxel, ANED: Alive no evidence of disease, AWD: Alive with disease, DDD:
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ANED: Alive no evidence of disease.
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prognosis for patients with early-stage seminoma treated
by orchiectomy and adjuvant radiotherapy or active sur-
veillance in a developing country. Unfortunately, there
are no previously published reports assessing outcomes
of seminoma patients in Jordan and as such we are un-
able to compare our results with those of another series.
Furthermore, to the best of our knowledge, there is only
one published study addressing testicular seminoma in a
Middle Eastern country [9]. This report -published inFigure 4 Number of patients diagnosed per year.1986- included a small number of patients treated in a
Saudi Arabian center prior to the implementation of
modern therapeutic guidelines. Nonetheless, and while
acknowledging the limitations of our study including the
small sample size and the short follow-up period, we
report excellent outcomes in lieu with previously pub-
lished Western reports.
Radical orchiectomy with ligation of the spermatic cord
at the level of the internal inguinal ring is considered the
standard treatment of seminoma [2]. Scrotal violation
should strongly be avoided, and as such, testicular biopsy
is not advised in patients with solid testicular tumors
[10,11]. Disappointingly, patients are still occasionally re-
ferred to our center with prior history of surgical violation
of the scrotum consequent to exploration or biopsy. In
our series, these patients were managed by either re-
excision or local irradiation to the scrotal scar. After
a median follow-up of 28 months (range, 7–74 months),
none of these patients developed relapse. This highlights
the effectiveness of these approaches in preventing local
recurrence.
Para-aortic radiotherapy is considered the standard
adjuvant treatment of early stage seminoma with disease-
specific survival rates approaching 100% [12,13]. The TE10
trial demonstrated the non-inferiority of para-aortic versus
dogleg radiotherapy fields [7]. Most of the patients in our
case series were treated by para-aortic fields and only a
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results of the TE18 trial were published and clearly
demonstrated the non-inferiority of lower (20 Gy) as
opposed to higher dose (30 Gy) para-aortic radiotherapy
[14]. Since then, we have adopted the recommendation of
this trial and 52 out of 70 (74.3%) patients with known
radiotherapy details received 20 Gy/10Fx.
Although the para-aortic field has emanated as the
standard radiation approach in seminoma patients [15],
Power et al. [16] reported the occurrence of ipsilateral
pelvic relapse in 3 patients that would otherwise have
been avoided if the radiation field was extended. In our
case series, one out of the 3 patients who developed re-
lapse harbored regional disease. In this patient, para-aortic
lymph node metastasis was detected via abdominal CT
scan 8 months after the completion of radiotherapy. Co-
registration of this image with the radiotherapy simulation
CT demonstrated that the relapse was actually in-field.
Detailed review of baseline abdominal CT was undertaken
in this patient and failed to reveal borderline and/or
grossly enlarged or suspicious pelvic or para-aortic masses.
The short time interval (from completion of radiotherapy
till the appearance of regional relapse) and the spatial loca-
tion of relapse (inside the radiation filed) support the fact
that this patient actually harbored a biologically aggressive
tumor from the start.
Due to the overwhelming success of the treatment and
the subsequent long-term survival, there has been growing
interest in decreasing treatment-related morbidity in semi-
noma patients [3]. Long-term complications of radiotherapy
include infertility and induction of secondary malignancy
[1]. Travis and colleagues [17] reported a 1.43 observed-to-
expected ratio of developing a second tumor in 29,000
long-term seminoma survivors. Although the absolute
number of radiation-induced second malignancy is low
[18], this has led several investigators to attempt substitut-
ing radiotherapy for chemotherapy in these patients. The
TE19 trial demonstrated the non-inferiority of single-
injection carboplatin over para-aortic and/or dogleg radio-
therapy at a dose of 20 to 30 Gy [19]. However, chemother-
apy also comes at the cost of undeniable side-effects.
Nonetheless, interest in active surveillance has largely been
driven by concerns about secondary malignancies asso-
ciated with radiotherapy [17]. Subsequent to the short
follow-up period and the retrospective nature of this case
series, we cannot address the occurrence and/or incidence
of second malignancies in our patient population.
Several reports have addressed the safety of surveil-
lance in the management of stage I seminoma [20].
Although relapse rates of 10-30% have been narrated in
patients with stage I seminoma [10,21,22], relapses are
usually detected early and salvage therapy is usually suc-
cessful with long-term survival [1]. However, since one
of the prerequisites of recommending active surveillancein patients with stage I seminoma is strict patient com-
pliance [23], one could argue against such approach in
developing countries such as Jordan where patient com-
pliance is still disappointingly low. In our series, none of
the patients under active surveillance developed relapse.
However, due to the small number of patients (3 patients),
we cannot draw conclusions on the applicability and safety
of active surveillance in the management of seminoma
patients in our community.
Although no clear predictors of relapse were found,
lymphovascular invasion, rete testis invasion and tumor
size have all been reported to significantly increase the
risk of relapse in patients with seminoma [24]. In our
series, all 3 patients presenting with relapse demon-
strated large tumors on initial pathological assessment
(4.6, 6, 8 cm). Nonetheless, no clear predictors of relapse
were found in our patient population.
Investigators have indicated that more than half of
patients with relapse initially exhibit indicative symptoms
and abnormal findings on physical examination high-
lighting the importance of patient education and meticu-
lous medical examination [12]. Less than 50% of
seminoma relapses present with radiological abnormal-
ities [25]. Furthermore, most cases of relapse are discov-
ered in the first 2 years after treatment. Our study
confirms this observation. All the 3 cases of relapse, in
our series, were diagnosed 8, 14, and 25 months after
completion of radiotherapy. However, late relapse –up to
10 years after treatment- has been previously reported
[11]. Nonetheless, no evidence exists supporting the
utilization of routine follow-up with computed tomog-
raphy beyond 3 years of treatment [12].
Conclusions
Our results confirm the excellent prognosis for patients
with early-stage seminoma treated by orchiectomy and
adjuvant radiotherapy or active surveillance in a develop-
ing country. Although all patients who developed relapse
demonstrated adverse pathological findings upon initial
assessment, no consistent predictor of relapse was found.
We have demonstrated the effectiveness of scrotal scar re-
excision or irradiation in patients with prior history of sur-
gical violation of the scrotum consequent to exploration or
biopsy.
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